David Dally
Chief Financial Officer

David Dally joined Singapore based MerLion Pharmaceuticals Pte Ltd in March 2007 as CFO and was appointed CEO in November 2013 Prior to MerLion, Mr. Dally was CFO at KuDOS Pharmaceuticals Ltd, an oncology drug discovery and development company in Cambridge, UK, which was sold to Astra Zeneca for $210 million in 2005 and subsequently he held the CFO role at Rhytec Ltd, a medical devices company David qualified as a chartered accountant with Ernst and Young before he joined Amersham plc in 1991 where he held a number finance roles including Manager of Strategic Planning and VP Finance North America, managing the merger of Amersham Life Science with Pharmacia Biotech.